SEC Form 4 · accession 0001651844-16-000023

NYMOX PHARMACEUTICAL CORP · NYMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 25, 2016

Accepted (ET)

Jul 29, 2016 · 6:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001018735

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
COMMON STOCK	Jul 25, 2016	P	2,500	$4.02	A	2,880,050	D
COMMON STOCK	Jul 26, 2016	P	2,500	$4.10	A	2,882,550	D
COMMON STOCK	Jul 26, 2016	P	2,500	$4.03	A	2,885,050	D
COMMON STOCK	Jul 27, 2016	P	2,500	$3.98	A	2,887,550	D
COMMON STOCK	Jul 28, 2016	P	2,500	$3.89	A	2,890,050	D
COMMON STOCK	Jul 28, 2016	P	2,500	$3.80	A	2,892,550	D
COMMON STOCK	Jul 28, 2016	P	2,500	$3.70	A	2,895,050	D
COMMON STOCK	Jul 29, 2016	P	2,500	$3.63	A	2,897,550	D
COMMON STOCK	Jul 29, 2016	P	2,500	$3.62	A	2,900,050	D
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST
COMMON STOCK	holding	—	—		—	45,050	I	TRUST

No Table II lines on this filing.